Annual report pursuant to Section 13 and 15(d)

Cover

v3.24.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2023
Apr. 01, 2024
Jun. 30, 2023
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2023    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2023    
Current Fiscal Year End Date --12-31    
Entity File Number 001-39126    
Entity Registrant Name CNS Pharmaceuticals, Inc.    
Entity Central Index Key 0001729427    
Entity Tax Identification Number 82-2318545    
Entity Incorporation, State or Country Code NV    
Entity Address, Address Line One 2100 West Loop South    
Entity Address, Address Line Two Suite 900    
Entity Address, City or Town Houston    
Entity Address, State or Province TX    
Entity Address, Postal Zip Code 77027    
City Area Code 800    
Local Phone Number 946-9185    
Title of 12(b) Security Common Stock    
Trading Symbol CNSP    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Elected Not To Use the Extended Transition Period false    
Entity Shell Company false    
Entity Public Float     $ 8,780,000
Entity Common Stock, Shares Outstanding   10,634,932  
Documents Incorporated by Reference [Text Block] Portions of this registrant’s definitive proxy statement for its 2023 Annual Meeting of Stockholders to be filed with the SEC no later than 120 days after the end of the registrant’s fiscal year are incorporated herein by reference in Part III of this Annual Report on Form 10-K.    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Auditor Firm ID 206    
Auditor Name MaloneBailey, LLP    
Auditor Location Houston, Texas